TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Equity/Stock(s)/Options - Dura Biotech; Thubrikar Aortic Valve Inc; MicroInterventional Devices; Supira; Admedus; TriFlo; Adona; Tioga
- Consultant Fee/Honoraria/Speaker's Bureau - Philips; Admedus; TriCares; Dura BioTech
- Grant Support/Research Contract - Edwards Lifesciences; Abbott; Medtronic; Boston Scientific Corporation; JenaValve